Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Treasury Shares (2019 - 2026)

Insight Molecular Diagnostics' Treasury Shares history spans 7 years, with the latest figure at $852000.0 for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 752.0% to $852000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $852000.0, a 752.0% increase, with the full-year FY2025 number at $852000.0, up 752.0% from a year prior.
  • Treasury Shares hit $852000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $917000.0 in the prior quarter.
  • Over the last five years, Treasury Shares for IMDX hit a ceiling of $1.5 million in Q3 2022 and a floor of $5000.0 in Q3 2023.
  • Historically, Treasury Shares has averaged $386666.7 across 5 years, with a median of $181000.0 in 2021.
  • Biggest five-year swings in Treasury Shares: tumbled 99.66% in 2023 and later surged 15020.0% in 2025.
  • Tracing IMDX's Treasury Shares over 5 years: stood at $121000.0 in 2021, then plummeted by 81.82% to $22000.0 in 2022, then plummeted by 77.27% to $5000.0 in 2023, then soared by 1900.0% to $100000.0 in 2024, then soared by 752.0% to $852000.0 in 2025.
  • Business Quant data shows Treasury Shares for IMDX at $852000.0 in Q4 2025, $917000.0 in Q3 2025, and $792000.0 in Q2 2025.